NASDAQ · ALZN
Healthcare · Biotechnology
$1.21
Down-$0.01 (-0.82%)
Updated Nov 1, 2026, 4:21 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ALZN
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ALZN closed at $1.21 after 20 trading sessions, down 14.18% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1.29 | $1.3288 | $1.21 | $1.21 | 25.03K |
| Oct 29, 2026 | $1.365 | $1.365 | $1.20 | $1.22 | 15.79K |
| Oct 28, 2026 | $1.155 | $1.23 | $1.12 | $1.19 | 21.37K |
| Oct 27, 2026 | $1.17 | $1.249 | $1.11 | $1.13 | 8.81K |
| Oct 26, 2026 | $1.10 | $1.155 | $1.10 | $1.14 | 25.7K |
| Oct 23, 2026 | $1.11 | $1.1899 | $1.10 | $1.13 | 29.09K |
| Oct 22, 2026 | $1.25 | $1.29 | $1.12 | $1.12 | 15.29K |
| Oct 21, 2026 | $1.29 | $1.39 | $1.25 | $1.25 | 10.55K |
| Oct 20, 2026 | $1.30 | $1.33 | $1.28 | $1.30 | 10.92K |
| Oct 19, 2026 | $1.34 | $1.345 | $1.31 | $1.33 | 6.52K |
| Oct 16, 2026 | $1.29 | $1.34 | $1.25 | $1.30 | 15.87K |
| Oct 15, 2026 | $1.32 | $1.335 | $1.28 | $1.28 | 14.97K |
| Oct 14, 2026 | $1.31 | $1.3955 | $1.31 | $1.35 | 23.16K |
| Oct 13, 2026 | $1.4297 | $1.4297 | $1.30 | $1.35 | 18.05K |
| Oct 12, 2026 | $1.40 | $1.4287 | $1.31 | $1.31 | 17.03K |
| Oct 9, 2026 | $1.43 | $1.43 | $1.34 | $1.34 | 13.3K |
| Oct 8, 2026 | $1.32 | $1.35 | $1.22 | $1.34 | 6.96K |
| Oct 7, 2026 | $1.37 | $1.42 | $1.34 | $1.37 | 18.89K |
| Oct 6, 2026 | $1.4352 | $1.4352 | $1.3428 | $1.37 | 32.05K |
| Oct 5, 2026 | $1.38 | $1.48 | $1.375 | $1.41 | 25.42K |
The latest Smart Investors Daily articles mentioning ALZN.
Company
Market Activity
Research & News
ALZN research
Company profile and research snapshot.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | Ascendiant Capital | Buy | — |
| Dec 22, 2025 | Ascendiant Capital | Buy | — |
| Sep 25, 2025 | Ascendiant Capital | Buy | — |
| Aug 21, 2025 | Ascendiant Capital | Buy | — |
| Mar 17, 2025 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 23, 2026
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA) stock rose
Yahoo · Oct 8, 2026
Alzamend Neuro (ALZN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Yahoo · Sep 22, 2026
Here is how Centene (CNC) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Yahoo · Sep 16, 2026
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated September 14, 2026, informing Alzame
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALZN.
